Abstract:Parkinson’s disease arises from the demise of dopaminergic neurons in the substantia nigra resulting from both environmental and hereditary factors. Drug interventions can solely delay disease progression, but cannot provide a cure. Therefore, cell replacement therapy may represent a promising treatment approach. Although the United States has already employed this technology, independent clinical and preclinical trials are mandatory for its inclusion in Russia. The iPSC technology enables the acquisition of personalized iPSC lines for each patient, nearly eradicating the immune response. While autologous cell therapy is theoretically ideal, the reprogramming of patient cells into iPSCs and subsequent differentiation for each patient incurs time and cost. Alternatively, differentiated derivatives of low immunogenic iPSCs, lacking HLA class I expression, can serve as a substitute. These cells evade the T-cell immune response, but other minor HLAs and cells from the innate immune system, like macrophages and NK cells, could still participate in the immune response’s development, although not as potent as in allogeneic transplantation. While these cell products don’t escape the immune response entirely, they lessen it significantly, potentially enabling the use of less severe immunosuppressive therapy. In this study, a protocol previously established in the cell biology laboratory was used to differentiate iPSCs lacking HLA class I expression and wild-type iPSCs into midbrain dopaminergic neuron precursors. A thorough analysis of the forerunners was performed and demonstrated appropriate patterning. The progenitors were then implanted into the brains of rats with 6-OHDA-induced Parkinsonism and followed for 6 months to compare their in vivo differentiation to standard differentiation in vitro. In addition, the systemic inflammatory response of the animals to the transplantation and the biodistribution of the injected cells were investigated. The literature inadequately addresses the question of which cells, other than dopaminergic neurons, differentiate during in vivo graft differentiation and potentially cause side effects in cell therapy. The literature suggests that only approximately 3% of transplanted cells differentiate into dopaminergic neurons, which is adequate to improve motor function in model animals. We found that a significant proportion of the progenitors differentiate into glial cells. The dynamics of maturation of transplanted neurons was evaluated. Thus, we approached preclinical testing of the cell product after having characterized in detail the dynamics of maturation and the composition of the graft. Comparison of in vivo and in vitro differentiation will allow evaluation of the quality of cellular material for transplantation.

Transplantation of Human Neural Progenitor Cells (NPC) into Putamina of Parkinsonian Patients: A Case Series Study, Safety and Efficacy Four Years after Surgery

Transplantation of Neural Precursor Cells in the Treatment of Parkinson Disease: an Efficacy and Safety Analysis

Clinical study of of neural stem cell transplantation for Parkinson's disease

Advancing Parkinson's disease treatment: cell replacement therapy with neurons derived from pluripotent stem cells

Transplantation of Human Neural Stem Cells in a Parkinsonian Model Exerts Neuroprotection Via Regulation of the Host Microenvironment

Preclinical evaluation of transaxial intraputaminal trajectory for enhanced distribution of grafted cells in Parkinson's disease

Personalized Ipsc-Derived Dopamine Progenitor Cells for Parkinson's Disease.

Combining physical & cognitive training with iPSC-derived dopaminergic neuron transplantation promotes graft integration & better functional outcome in parkinsonian marmosets

Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study

Co-Transplantation of Gdnf-Overexpressing Neural Stem Cells and Fetal Dopaminergic Neurons Mitigates Motor Symptoms in A Rat Model of Parkinson'S Disease

Interventional Strategies for Parkinson Disease: Can Neural Precursor Cells Forge a Path Ahead?

Transplantation in Parkinson’s Disease

Human stem cell transplantation for Parkinson’s disease: A systematic review of survival and maturation of progenitors derived from human embryonic or induced stem cells in Parkinsonian models

Autologous Neural Stem Cell Transplantation: A New Treatment Option for Parkinson’s Disease?

The fate of iPSCs-derived low immunogenic dopaminergic neuron precursors after transplantation into the striatum of rats with 6-OHDA-induced parkinsonism

Secretome of Undifferentiated Neural Progenitor Cells Induces Histological and Motor Improvements in a Rat Model of Parkinson's Disease

Transplantation of human retinal pigment epithelium cells in the treatment for Parkinson disease.

Dual Effects of Human Placenta-Derived Neural Cells on Neuroprotection and the Inhibition of Neuroinflammation in a Rodent Model of Parkinson's Disease

Transplantation of Human Neural Stem Cell Prevents Symptomatic Motor Behavior Disability in a Rat Model of Parkinson’s Disease

Grafted neural stem cells migrate to substantia nigra and improve behavior in Parkinsonian rats

Neural Transplantation and Trophic Factors in Parkinson's Disease: Special Reference to Chromaffin Cell Grafting, NGF Support from Pretransected Peripheral Nerve, and Encapsulated Dopamine-Secreting Cell Grafting